These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33815744)

  • 1. Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies.
    Kang YC; Chen MH; Lin CY; Lin CY; Chen YT
    Ther Adv Drug Saf; 2021; 12():2042098621997727. PubMed ID: 33815744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
    Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
    Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
    [No Abstract]   [Full Text] [Related]  

  • 3. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
    Dickman KG; Chen CH; Grollman AP; Pu YS
    World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of aristolochic acid exposure on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy.
    Zhong W; Zhang L; Ma J; Shao S; Lin R; Li X; Xiong G; Fang D; Zhou L
    Onco Targets Ther; 2017; 10():5775-5782. PubMed ID: 29255365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
    Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
    Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological characteristics and outcomes of synchronous renal cell carcinoma and urothelial carcinoma: A population-based analysis.
    Wu K; Liu X; Wang Y; Wang X; Li X
    Front Public Health; 2022; 10():994351. PubMed ID: 36388369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.
    Karanović S; Ardin M; Tang Z; Tomić K; Villar S; Renard C; Venturini E; Lorch AH; Lee DS; Stipančić Ž; Slade N; Vuković Brinar I; Dittrich D; Karlović K; Borovečki F; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J
    Int J Cancer; 2022 Jan; 150(2):374-386. PubMed ID: 34569060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
    Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
    Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients.
    Xiong G; Yao L; Hong P; Yang L; Ci W; Liu L; He Q; Gong K; Li X; Zhou L
    Cancer Manag Res; 2018; 10():6627-6639. PubMed ID: 30584358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latency period of aristolochic acid-induced upper urinary tract urothelial carcinoma.
    Jhuang JR; Chiu PC; Hsieh TC; Chen CH; Pu YS; Lee WC
    Front Public Health; 2023; 11():1072864. PubMed ID: 36969664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies.
    Mertens LS; Sharma V; Matin SF; Boorjian SA; Houston Thompson R; van Rhijn BWG; Masson-Lecomte A
    Eur Urol Open Sci; 2023 Mar; 49():60-66. PubMed ID: 36793750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.
    Seisen T; Peyronnet B; Dominguez-Escrig JL; Bruins HM; Yuan CY; Babjuk M; Böhle A; Burger M; Compérat EM; Cowan NC; Kaasinen E; Palou J; van Rhijn BW; Sylvester RJ; Zigeuner R; Shariat SF; Rouprêt M
    Eur Urol; 2016 Dec; 70(6):1052-1068. PubMed ID: 27477528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.
    Yates DR; Catto JW
    World J Urol; 2013 Feb; 31(1):21-9. PubMed ID: 22986906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis.
    Quhal F; Mori K; Sari Motlagh R; Laukhtina E; Pradere B; Rouprêt M; Necchi A; Moschini M; Shariat SF
    Int J Clin Oncol; 2020 Jun; 25(6):1037-1054. PubMed ID: 32206939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph node dissection for upper tract urothelial carcinoma: A systematic review.
    Chan VW; Wong CHM; Yuan Y; Teoh JY
    Arab J Urol; 2020 Jul; 19(1):37-45. PubMed ID: 33763247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center.
    Fang D; Zhang L; Li X; Xiong G; Chen X; Han W; He Z; Zhou L
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):477-85. PubMed ID: 24469253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence, clinicopathological features, and prognosis in upper tract urinary carcinoma patients with severe preoperative chronic kidney disease.
    Bao Z; Du Y; Yuan Y; Zhu Y; Qian C; Zhan Y; Fang D; Xiong G; Zhang L; Li X; Zhou L
    Transl Androl Urol; 2019 Dec; 8(6):641-650. PubMed ID: 32038960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature.
    Hassler MR; Bray F; Catto JWF; Grollman AP; Hartmann A; Margulis V; Matin SF; Roupret M; Sfakianos JP; Shariat SF; Faltas BM
    Eur Urol; 2020 Aug; 78(2):209-220. PubMed ID: 32571725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of the Controlling Nutritional Status score on patients undergoing nephrectomy for upper tract urothelial carcinoma or renal cell carcinoma: a systematic review and meta-analysis.
    Chen J; Cao D; Peng Z; Song P; Liu Z; Yang L; Wang L; Zhou J; Wei Q; Dong Q
    Br J Nutr; 2022 Jul; 128(2):217-224. PubMed ID: 34338171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.